FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10					
Express Mail Label Number	per Date of Deposit				

Form PTO-1390-MOD Ü. S. Department of Commerce Patent and Trademark Office (REV 10-96)		ATTORNEY'S DOCKET NUMBER 33599-US-PCT								
TRANSMITTAL LETTER TO T	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
DESIGNATED/ELECTED O	· · · · · · · · · · · · · · · · · · ·									
CONCERNING A FILING UN										
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
PCT/EP2005/001635 TITLE OF INVENTION	17 February 2005 (17.02.05)	18 February 2004 (18.02.04)								
7H-PYRROLOPYRIMIDINE DERIVATIVES										
APPLICANT(S) FOR DO/EO/US										
CARAVATTI ET AL.										
Applicant herewith submits to the United States De	esignated/Elected Office (DO/EO/US) th	ne following items and other information:								
1. This is a FIRST submission of items cond	erning a filing under 35 U.S.C. 371.									
 This is a SECOND or SUBSEQUENT sufficient. This express request to begin national expression. 										
examination until the expiration of the app	olicable time limit set in 35 U.S.C. 371(b	and PCT Articles 22 and 39(1).								
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.										
5. A copy of the International Application as										
a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau). b. ☑ has been transmitted by the International Bureau. (See Form PCT/IB/308)										
c. is not required, as the application	c. is not required, as the application was filed in the United States Receiving Office (RO/US).									
 6. A translation of the International Application 7. Amendments to the claims of the International Application 		′35 U.S.C.371(c)(3)).								
a. 🔲 are transmitted herewith (required	f only if not transmitted by the Internation									
	 b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. 									
d. have not been made and will not	be made.									
9. X An executed Declaration and Power of Al	 A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). 									
10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
ον ποχογι										
Items 11. to 16. below concern document(s) or	information included.									
11. An Information Disclosure Statement und	er 37 CFR 1.97 and 1.98.									
12. An assignment document for recording.	A separate cover sheet in compliance w	ith 37 CFR 3.28 and 3.31 is included.								
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminar	v om on den ant									
A SECOND OF SOBSEQUENT PREMIMAR	y amenoment.									
14. An Application Data Sheet under 37 CFR	An Application Data Sheet under 37 CFR 1.76.									
15. A substitute specification.										
16. A change of power of attorney and/or add	lress letter.									
17. A computer-readable form of the sequence	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.									
	A second copy of the published International Application under 35 U.S.C. 154(d)(4).									
19. A second copy of the English language tr	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).									
20. Other items or information:										

U.S. APPLICATION NO	(if known, see 37 CFR 1.5)	I	INTERNATIONAL APPLICATION NO. ATTORNEY'S I PCT/EP2005/001635 33599-US			OCKET NUMBER -PCT		
The following fe	es are submitted:	1				CALCULATIO	NS PTO USE	
						ONLY	·	
21. 🛭 Basi	1. 🗵 Basic national fee							
Examination Fee If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)								
. All other situations. \$200								
23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority. \$ If International Search Report was prepared and provided to the Office. \$400 All other situations. \$								
TOTAL OF 21, 22 AND 23 =								
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra sheets		additional 50 or fraction additional 50 or fraction at the perion at the perion at the perion and the perion at the period at th	on F	RATE			
53 - 100 =	/50 =	thorous (round t	0	X \$	250	\$		
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).								
CLAIMS Total claims	CLAIMS NUMBER FILED NUMBER EXTRA RATE					¢.		
Independent cla	14 ims 2	- 20 =	0	X \$ X	50 200	\$ \$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360								
TOTAL OF ABOVE CALCULATIONS =						\$ 900		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).						\$		
SUBTOTAL =						\$ 900		
Processing fee of \$130 for furnishing the English translation later than						\$		
TOTAL NATIONAL FEE =						\$ 900		
			1.21(h)). The assignm \$40 per property	ient must be a	ccompanied +	\$		
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + TOTAL FEES ENCLOSED =						\$ 900		
						Amount to be: refunded	\$	
						charged	\$	
	k in the amount of \$_		_ to cover the above fe					
	charge Deposit Acci te copy of this form i		4 in the name of Novar	tis in the amou	ınt of \$900 to	cover the above	fees. A	
c. 🛮 The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
Customer No. 00 Novartis Corpora One Hea	te Intellectual Proper alth Plaza, Building 1	ently: ty 04	Rec Atto Rec	gina Bautista Irney for Applic I. No. 46,280 7) 871-3356	iutut			
∟ast Hai	nover, NJ 07936-108	υ						